Experience

Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of 44,550,000 common shares, including common shares in the form of…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are intended to improve liquidity, extend debt maturities and enable…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…

Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 4,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by Teladoc, Inc. of $275 million aggregate principal amount of its 3.00% convertible senior notes due 2022…

Davis Polk advised the dealer manager on a cash tender offer by Bristol-Myers Squibb Company for any and all of its 5.875% notes due 2036, 6.125% notes due 2038 and 6.875% debentures due…

Davis Polk advised the joint book-running managers in connection with a $260.8 million SEC-registered offering of 3,622,500 shares of common stock of Loxo Oncology, Inc. The common stock is…